作者：中国临床肿瘤学会结直肠癌专家委员会

Authors: Committee of Colorectal Experts, Chinese Society of Clinical Oncology

摘要：

对于接受标准一线治疗达到疾病控制的转移性结直肠癌（mCRC），后续治疗策略的制订应在维持疗效的同时注重改善患者生活质量。化疗联合抗表皮生长因子受体（EGFR）单抗是RAS野生型mCRC患者的标准一线治疗方案。当一线含抗EGFR单抗诱导治疗达到最佳疗效、且处于疾病缓解或稳定状态时，含抗EGFR单抗维持治疗方案可在维持疗效获益的同时，降低毒副反应和提高患者生活质量。本共识基于循证医学和临床实践，进一步明确抗EGFR单抗维持治疗的应用时机、方案选择、不良反应管理和后续策略选择，为抗EGFR单抗维持治疗提供临床应用规范化标准和指导，以期使患者的治疗最大化获益。

关键词： 结直肠肿瘤，转移性；RAS野生型；抗EGFR单抗；维持治疗

Abstract：

For patients with metastatic colorectal cancer (mCRC) who achieve disease control during first-line standard therapy, post-induction strategies should emphasize on quality of life improvement while maintaining disease control. Chemotherapy combined with anti-epidermal growth factor receptor (EGFR) monoclonal antibody is the standard first-line treatment for RAS wild-type mCRC patients. After anti-EGFR-based first-line induction therapy achieves at least stable disease, anti-EGFR-based maintenance treatment could maintain disease control while keeping a good safety profile. Based on research evidence and clinical practice, the Chinese expert consensus on anti-EGFR-based maintenance strategy for RAS wild-type mCRC aims to further clarify the treatment timing, regimen options, adverse reaction management and followup strategy, providing standardized guidance to maximize the clinical benefit in RAS wild-type mCRC.

Key Words:  Colorectal neoplasms, metastatic; RAS wild-type; Anti-EGFR monoclonal antibody; Maintenance therapy

注：网络优先发布